One of the most advanced efforts to target p53 for cancer therapy involves efforts to inhibit MDM2 in tumors harboring WT p53, which leads to the development of Nutlin-3 and peptide inhibitors of MDM2 and MDMX [16,17]. The gene discussed is TP53; the disease is cancer.